Skip to content
approvedGrowth Hormone

Somatostatin

Also known as: SST-14, SRIF, Growth Hormone-Inhibiting Hormone, GHIH, Somatotropin Release-Inhibiting Factor

Somatostatin is a naturally occurring cyclic peptide hormone produced in the hypothalamus, gastrointestinal tract, and pancreatic delta cells. The predominant form (SST-14) is a 14-amino-acid cyclic peptide that broadly inhibits growth hormone, insulin, glucagon, gastrin, secretin, and numerous other hormones. While native somatostatin has a very short half-life (~2 minutes), its discovery led to the development of longer-acting synthetic analogs (octreotide, lanreotide, pasireotide) that are FDA-approved for acromegaly, neuroendocrine tumors, and Cushing disease.

4 cited references·5 researched benefits

Quick Answer

Somatostatin is a 14-amino-acid cyclic peptide hormone produced in the hypothalamus, gut, and pancreas that acts as a master inhibitory regulator, suppressing growth hormone, insulin, glucagon, gastrin, and many other hormones. Its extremely short half-life (~2 minutes) limits direct clinical use, but it spawned the development of three FDA-approved synthetic analogs — octreotide, lanreotide, and pasireotide — used to treat acromegaly, neuroendocrine tumors, and Cushing disease.

Key Facts

Mechanism
Somatostatin binds five G-protein-coupled receptor subtypes (SSTR1–SSTR5) expressed across diverse tissues. Receptor activation inhibits adenylyl cyclase (reducing cAMP), opens potassium channels (hyperpolarizing cells), closes calcium channels (blocking exocytosis), and activates protein phosphatases. In the pituitary, SSTR2 and SSTR5 mediate growth hormone and TSH suppression. In the pancreas, SSTR2 inhibits glucagon (alpha cells) and SSTR5 inhibits insulin (beta cells). In the gut, it suppresses gastrin, secretin, cholecystokinin, VIP, and motilin, reducing gastric acid secretion, bile flow, and intestinal motility. It also has antiproliferative effects through SSTR2/SSTR3-mediated cell cycle arrest and apoptosis induction.
Research Status
approved
Half-Life
~1–3 minutes
Molecular Formula
C₇₆H₁₀₄N₁₈O₁₉S₂
Primary Use
Growth Hormone
Table of Contents

Benefits

  • Growth hormone suppression — primary endogenous inhibitor of GH release from the anterior pituitary, critical for GH axis regulationstrong
  • Gastrointestinal hormone regulation — inhibits gastrin, secretin, CCK, VIP, and motilin, reducing acid secretion and GI motilitystrong
  • Antiproliferative effects — SSTR2/3-mediated cell cycle arrest provides basis for neuroendocrine tumor treatment with analogsstrong
  • Variceal bleeding management — IV somatostatin reduces portal pressure and is used to control acute esophageal variceal hemorrhagestrong
  • Pancreatic fistula management — reduces pancreatic exocrine secretion, used post-operatively to manage pancreatic leaksmoderate

Dosage Protocols

RouteDosage RangeFrequencyNotes
Intravenous infusion (native somatostatin)250 mcg bolus, then 250–500 mcg/hourContinuous infusionNative somatostatin is used only in hospital settings for acute indications (variceal bleeding, pancreatic fistula) due to its ~2-minute half-life requiring continuous infusion. Synthetic analogs (octreotide, lanreotide) are used for chronic conditions.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Hyperglycemia or hypoglycemia — dual inhibition of insulin and glucagon can unpredictably affect blood glucosecommon
  • Nausea and abdominal discomfort — GI effects from broad hormone suppressioncommon
  • Bradycardia — heart rate slowing via vagal effects; monitor in cardiac patientsrare
  • Gallstone formation — with prolonged analog use; reduced gallbladder motility promotes bile stasisrare
  • Rebound hormone hypersecretion — abrupt discontinuation may cause temporary hormone reboundrare

Frequently Asked Questions

Why is native somatostatin rarely used clinically?
Native somatostatin (SST-14) has a plasma half-life of only 1–3 minutes, requiring continuous intravenous infusion for any clinical effect. This limits its use to acute hospital settings. The development of longer-acting synthetic analogs (octreotide: half-life ~90 minutes; lanreotide: half-life ~23 days in depot form) solved this problem. These analogs have selective receptor affinity profiles and practical dosing schedules, making them suitable for chronic outpatient treatment of acromegaly and neuroendocrine tumors.
What is the relationship between somatostatin and growth hormone?
Somatostatin is one of two primary hypothalamic regulators of GH secretion: GHRH stimulates GH release and somatostatin inhibits it. Together, they create the pulsatile GH secretion pattern, with somatostatin withdrawal (during deep sleep, for example) permitting GH pulses. In acromegaly, where a pituitary adenoma overproduces GH, somatostatin analogs suppress this excess production. This yin-yang relationship between GHRH and somatostatin is fundamental to neuroendocrine physiology.
What are the five somatostatin receptor subtypes?
SSTR1–SSTR5 are expressed in tissue-specific patterns: SSTR2 (most widely expressed, dominant in pituitary GH cells and GI tract — primary target of octreotide/lanreotide); SSTR5 (pituitary ACTH cells — targeted by pasireotide for Cushing disease); SSTR1 and SSTR4 (predominantly neural/retinal); SSTR3 (involved in apoptosis signaling). Different analogs have different receptor selectivity: octreotide/lanreotide are SSTR2-preferring, while pasireotide has broader SSTR1/2/3/5 activity.
How was somatostatin discovered?
Somatostatin was discovered in 1973 by Roger Guillemin and colleagues at the Salk Institute while searching for hypothalamic releasing factors. They isolated a 14-amino-acid peptide from ovine hypothalamic extracts that inhibited growth hormone secretion — hence "somatostatin" (soma = body, statin = inhibitor). Guillemin received the Nobel Prize in 1977 for this and other hypothalamic hormone discoveries. The broader role of somatostatin as a universal endocrine inhibitor was recognized subsequently.
Does somatostatin play a role in aging?
Somatostatin tone increases with aging, contributing to the progressive decline in GH secretion (somatopause). This age-related GH decline is associated with decreased lean body mass, increased adiposity, reduced bone density, and diminished immune function. Some researchers hypothesize that reducing somatostatinergic tone (through GHRH analogs or GH secretagogues) could partially reverse these aging changes, though this remains an area of active investigation with significant controversy regarding long-term safety.

References

  1. 1
    Somatostatin and its receptor family(2004)PubMed ↗
  2. 2
    Hypothalamic somatostatin: discovery, functions, and clinical significance(2000)PubMed ↗
  3. 3
    Somatostatin analogs in the treatment of gastroenteropancreatic neuroendocrine tumors(2010)PubMed ↗
  4. 4
    Clinical pharmacology of somatostatin analogs: a comprehensive review(2017)PubMed ↗

Latest Research

Last updated: 2026-02-19